Why FDA's Approval of First Cannabidiol (CBD) Treatment is a Major Milestone for CBD Industry

PALM BEACH, Florida, June 27, 2018 /PRNewswire/ --

FN Media Group News Commentary 

There's no doubt that cannabidiol or CBD has seen a remarkable increase in popularity across the globe. The popularity is sure to grow even more as the U.S. Food and Drug Administration (FDA) approved the use of a drug derived from marijuana for the first time Monday, giving the go ahead to treat two rare forms of epilepsy with the compound cannabidiol, also known as CBD, found in hemp and marijuana. The FDA approved GW Pharmaceuticals PLC-ADR 's (NASDAQ:GWPH) Epidiolex for the treatment of epilepsy, specifically for people who suffer with Lennox-Gastaut and Dravet syndromes. This milestone could spur more research into a drug that remains illegal under federal law, despite growing legalization for recreational and medical use. Active companies in the markets include: PotNetwork Holdings Inc. (OTC:POTN), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Hemp, Inc. (OTC:HEMP), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED).

PotNetwork Holdings Inc. (OTCPK:POTN) BREAKING NEWS: PotNetwork Holdingsis announces that the Company is in the process of filing an amendment to its articles of incorporation with the state of Colorado for a name change from PotNetwork Holdings, Inc. to "BioTech Hemp, Inc. ". This name change reflects the Company's focus on Diamond CBD's sales momentum and expanding product lines, which better reflects its current and future business strategy and industry scope. Following the filing with the state of Colorado, the Company plans to file for a name listing and trading symbol change with FINRA.

As revenues year-to-date for 2018 already exceed $10 million, the Company's repositioning initiative is designed to signal to the market its mission to be a continually thriving, socially-responsible family of brands dedicated to strengthening its evolving leadership position in the distribution and marketing of CBD products. This filing follows the recent announcement that its Board of Directors has directed the Company's counsel to prepare a Form 10 to be filed with the Securities and Exchange Commission, to become a fully reporting issuer with the SEC. This action is fundamental to the Company's efforts to demonstrate heightened transparency to its investors and bring the Company greater visibility and credibility before a substantially larger group of qualified investors. In addition, once the Form 10 filing is completed, the Company plans to apply to OTC Markets for an uplisting to the OTCQB® Venture Market.